<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802267</url>
  </required_header>
  <id_info>
    <org_study_id>ICT8</org_study_id>
    <nct_id>NCT02802267</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy</brief_title>
  <official_title>Efficacy Study of Inecalcitol in Combination With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hybrigenics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hybrigenics Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of the addition of inecalcitol to decitabine treatment on overall
      survival in previously untreated AML patients aged 65 years or more who are randomly assigned
      to receive decitabine with or without inecalcitol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>inecalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two tablets of Inecalcitol 2mg each (total 4mg) taken orally every other day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two tablets of placebo 2mg each (total 4mg) taken orally every other day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inecalcitol</intervention_name>
    <description>vitamin D receptor agonist</description>
    <arm_group_label>inecalcitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Patients aged 65 to &lt; 75 years with at least one non severe comorbidity ie disease or
        syndrome with mild to moderate clinical or diagnostic observations or lab abnormalities
        which could increase the risk of toxicity and/or early death of intensive chemotherapy in
        the opinion of the investigator and are not contra-indicated for non-intensive
        chemotherapy.

        or ≥ 75 years with or without any comorbidity at the time of the informed consent
        signature;

        • Newly diagnosed, untreated de novo or secondary AML according to WHO classification;

        Exclusion Criteria:

          -  Prior or current treatment with chemotherapy for any myeloid disorder (excluding
             hydroxyurea) or radiotherapy for extramedullary involvement within 2 weeks of
             randomization;

          -  Prior treatment with decitabine, azacitidine, or cytarabine;

          -  Prior malignancies for 5 years with exception of basal cell, squamous cell carcinoma
             of the skin, or carcinoma &quot; in situ &quot; of the cervix or breast;

          -  Chronic myelogenous or acute promyelocytic leukaemia;

          -  Known CNS involvement;

          -  Patient eligible to bone marrow or stem cell transplant;

          -  WBC ≥ 30.000/mm3;

          -  Impaired renal function with Creatinine clearance &lt; 30 mL/min/1.73m² according to the
             MDRD formula;

          -  Serum bilirubin ≥ 2.5 x ULN and/or AST and/or ALT ≥ 2.5 x ULN (upper limit of normal
             value);

          -  Calcemia ≥ 2.65 mmol/L (106 mg/L) at screening assessment (corrected with
             albuminemia);

          -  History of diseases known to be associated with calcium disorders: ongoing
             hyperparathyroidism, sarcoidosis….;

          -  Presence or history of symptomatic kidney stones in the last 5 years;

          -  Hypersensitivity to any of the excipients of decitabine (Potassium dihydrogen
             phosphate (E340) ; Sodium hydroxide (E524) ; Hydrochloric acid (for pH adjustment) or
             to the excipient of inecalcitol tablets (lactose);

          -  Current use of drugs known to influence serum calcium (such as thiazide diuretics,
             teriparatide, calcitonin and multivitamin supplements containing &gt; 400 IU of vitamin D
             or calcium);

          -  Current use of digitalis;

          -  Current use of drugs which could influence bioavailability of inecalcitol (such as
             magnesium-containing antacids, bile-resin binders);

          -  Use of any other experimental drug or therapy or vitamin D supplementation within 4
             weeks of randomization;

          -  Known HIV;

          -  Patients who are eligible for intensive induction therapy with curative intent;

          -  Refractory congestive heart failure;

          -  Active infection resistant to anti-infective therapy;

          -  Documented pulmonary disease with DLCO ≤ 65% or FEV1≤ 65%, or dyspnea at rest or
             requiring oxygen, or any pleural neoplasm or uncontrolled lung neoplasm;

          -  Liver cirrhosis Child B or C or acute viral hepatitis;

          -  Current mental illness requiring psychiatric hospitalization, institutionalization or
             intensive outpatient management, or current cognitive status that produces dependence
             (as confirmed by the specialist) not controlled by the caregiver;

          -  Uncontrolled neoplasia;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Dufour-Lamartinie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hybrigenics Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shankar Srinivasan, PhD</last_name>
    <phone>+1-2246221775</phone>
    <email>ssrinivasan@hybrigenics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Francois Dufour-Lamartinie, MD</last_name>
    <phone>+33-158103805</phone>
    <email>jfdufour@hybrigenics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scripps Health</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marin Xavier, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Boyka S Petrov</last_name>
      <email>Petrov.Boyka@scrippshealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center-Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy M Pantin, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Christine Sanchez</last_name>
      <email>csanchez@augusta.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khin Win, MBBS, CCRC</last_name>
      <email>khin.win@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Tiffany Gordon</last_name>
      <email>tiffany.gordon@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Edwin Kingsley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Alliance</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaylee Deutsch, MHA, CCRP</last_name>
      <email>kdeutsch@nmcca.org</email>
    </contact>
    <contact_backup>
      <last_name>April Encee, RN, OCN</last_name>
      <email>aencee@salud.unm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cecilia Arana-Yi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute, Duke Univ Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Rizzieri, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Rachel Stowe</last_name>
      <email>rachel.stowe@duke.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Texas; M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Cortes, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Jane A Autry</last_name>
      <email>JAAutry@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ProHealth Care Inc</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dawn Minikel</last_name>
      <email>dawn.minikel@phci.org</email>
    </contact>
    <contact_backup>
      <last_name>Amelia Crouse</last_name>
      <email>amelia.crouse@phci.org</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Wassenaar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Necker Hospital- APHP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Hermine, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

